XML 56 R26.htm IDEA: XBRL DOCUMENT
v3.3.0.814

Segments of Business and Geographic Areas (Tables) | 9 Months Ended
--- | ---
Sep. 27, 2015
Segment Reporting [Abstract] |
Sales By Segment Of Business |
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | September 27, 2015 |  | September 28, 2014 |  | Percent Change
Consumer |  |  |  |  |  |
United States |  | $ | 1,277 |  |  | 1,173 |  |  | 8.9 | %
International |  | 2,037 |  |  | 2,416 |  |  | (15.7 | )
Total |  | 3,314 |  |  | 3,589 |  |  | (7.7 | )
Pharmaceutical |  |  |  |  |  |
United States |  | 4,509 |  |  | 4,723 |  |  | (4.5 | )
International |  | 3,185 |  |  | 3,584 |  |  | (11.1 | )
Total |  | 7,694 |  |  | 8,307 |  |  | (7.4 | )
Medical Devices |  |  |  |  |  |
United States |  | 3,005 |  |  | 2,946 |  |  | 2.0 |
International |  | 3,089 |  |  | 3,625 |  |  | (14.8 | )
Total |  | 6,094 |  |  | 6,571 |  |  | (7.3 | )
Worldwide |  |  |  |  |  |
United States |  | 8,791 |  |  | 8,842 |  |  | (0.6 | )
International |  | 8,311 |  |  | 9,625 |  |  | (13.7 | )
Total |  | $ | 17,102 |  |  | 18,467 |  |  | (7.4 | )%
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 27, 2015 |  | September 28, 2014 |  | Percent Change
Consumer |  |  |  |  |  |
United States |  | $ | 3,991 |  |  | 3,802 |  |  | 5.0 | %
International |  | 6,196 |  |  | 7,088 |  |  | (12.6 | )
Total |  | 10,187 |  |  | 10,890 |  |  | (6.5 | )
Pharmaceutical |  |  |  |  |  |
United States |  | 13,423 |  |  | 13,076 |  |  | 2.7 |
International |  | 9,943 |  |  | 11,238 |  |  | (11.5 | )
Total |  | 23,366 |  |  | 24,314 |  |  | (3.9 | )
Medical Devices |  |  |  |  |  |
United States |  | 8,980 |  |  | 9,300 |  |  | (3.4 | )
International |  | 9,730 |  |  | 11,573 |  |  | (15.9 | )
Total |  | 18,710 |  |  | 20,873 |  |  | (10.4 | )
Worldwide |  |  |  |  |  |
United States |  | 26,394 |  |  | 26,178 |  |  | 0.8 |
International |  | 25,869 |  |  | 29,899 |  |  | (13.5 | )
Total |  | $ | 52,263 |  |  | 56,077 |  |  | (6.8 | )%
Operating profit by segment of business |
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | September 27, 2015 |  | September 28, 2014 |  | Percent Change
Consumer (1) |  | $ | 811 |  |  | 407 |  |  | 99.3 | %
Pharmaceutical(2) |  | 2,732 |  |  | 3,247 |  |  | (15.9 | )
Medical Devices(3) |  | 835 |  |  | 3,399 |  |  | (75.4 | )
Segments operating profit |  | 4,378 |  |  | 7,053 |  |  | (37.9 | )
Less: Expense not allocated to segments (4) |  | 256 |  |  | 243 |  |  |
Worldwide income before taxes |  | $ | 4,122 |  |  | 6,810 |  |  | (39.5 | )%
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 27, 2015 |  | September 28, 2014 |  | Percent Change
Consumer (1) |  | $ | 1,772 |  |  | 1,588 |  |  | 11.6 | %
Pharmaceutical(2) |  | 9,816 |  |  | 9,921 |  |  | (1.1 | )
Medical Devices(3) |  | 4,640 |  |  | 7,069 |  |  | (34.4 | )
Segments operating profit |  | 16,228 |  |  | 18,578 |  |  | (12.6 | )
Less: Expense not allocated to segments (4) |  | 790 |  |  | 718 |  |  |
Worldwide income before taxes |  | $ | 15,438 |  |  | 17,860 |  |  | (13.6 | )%
(1) Includes a gain of $229 million from the divestiture of the SPLENDA® brand recorded in the fiscal third quarter and fiscal nine months of 2015. Includes a gain of $388 million from the divestiture of the K-Y® brand recorded in the fiscal nine months of 2014. (2) Includes litigation expense of $136 million in the fiscal nine months of 2015. Includes a gain of $981 million recorded in the fiscal nine months of 2015 from the divestiture of the U.S. license rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol extended-release tablets), and NUCYNTA® (tapentadol) oral solution. Includes an additional year of the Branded Prescription Drug Fee of $220 million recorded in the fiscal third quarter and fiscal nine months of 2014. (3) Includes litigation expense of $409 million related to product liability and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal third quarter of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $225 million, Synthes integration costs of $167 million and $126 million for costs associated with the DePuy ASR TM Hip program recorded in the fiscal third quarter of 2014. Includes $148 million for costs associated with the DePuy ASR TM Hip program, Synthes integration costs of $113 million and a $0.3 billion intangible asset write-down related to Acclarent recorded in the fiscal nine months of 2015. Includes a net gain of $1,948 million from the divestiture of the Ortho-Clinical Diagnostics business, litigation expense of $501 million, Synthes integration costs of $429 million and $126 million for costs associated with the DePuy ASR TM Hip program recorded in the fiscal nine months of 2014. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas |
|  | Fiscal Third Quarters Ended
(Dollars in Millions) |  | September 27, 2015 |  | September 28, 2014 |  | Percent Change
United States |  | $ | 8,791 |  |  | 8,842 |  |  | (0.6 | )%
Europe |  | 3,802 |  |  | 4,446 |  |  | (14.5 | )
Western Hemisphere, excluding U.S. |  | 1,463 |  |  | 1,820 |  |  | (19.6 | )
Asia-Pacific, Africa |  | 3,046 |  |  | 3,359 |  |  | (9.3 | )
Total |  | $ | 17,102 |  |  | 18,467 |  |  | (7.4 | )%
|  | Fiscal Nine Months Ended
(Dollars in Millions) |  | September 27, 2015 |  | September 28, 2014 |  | Percent Change
United States |  | $ | 26,394 |  |  | 26,178 |  |  | 0.8 | %
Europe |  | 11,993 |  |  | 14,387 |  |  | (16.6 | )
Western Hemisphere, excluding U.S. |  | 4,603 |  |  | 5,378 |  |  | (14.4 | )
Asia-Pacific, Africa |  | 9,273 |  |  | 10,134 |  |  | (8.5 | )
Total |  | $ | 52,263 |  |  | 56,077 |  |  | (6.8 | )%

X
- Definition Sales by segment of business. + References No definition available. + Details
Name: | jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix: | jnj_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8813-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8736-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration